Mylan MYL shares are trading lower by $2.73 at $35.51 in Tuesday's session.
The catalyst for the decline is a report that attorney generals from 46 states will expand a suit related to alleged price fixing among generic drug-makers to 18 companies involving 15 different medicines.
After a flat open, Mylan found resistance just above Monday's close ($38.24), reaching $38.44 and retreated back to the $38.00 area. It was attempting to absorb the news when a wave of sellers attacked the stock around 10:55 a.m. EST.
Following a quick rebound off $34.72, Mylan's stock bounced into the $36.00 handle before coming down to make a new low for the session at $34.27. That marks its lowest level since it bottomed ahead of its FDA approval of first generic approval of Copaxone at $31.84 and leaped to $37.80 the following session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
